# Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

> **NCT07012447** · PHASE2 · RECRUITING · sponsor: **yuejun Liu** · enrollment: 32 (estimated)

## Conditions studied

- Early T Acute Lymphoblastic Leukemia
- T-Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia, T/Myeloid, Nos

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT07012447
- **Lead sponsor:** yuejun Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07012447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07012447, "Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07012447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*